Stock listing
OTC:NKGN NKGen Biotech Inc. Stock
Follow NKGen Biotech Inc. into a list and get an email when it puts out news.
Share price · OTC:NKGN
$0.0030 USD 0.0000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.0030 – $0.0030 USDNov 20, 2026
- Volume
- 1,500 sharesNov 20, 2026
- Market cap
- $391,807 USDAt the close on Nov 20, 2026 · price × 130.6M shares outstanding
- 52-week range
- $0.0010 – $0.2000 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $21 USDMedian day 150 shares · 29 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:NKGN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 1,500 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 3,100 | |
| $0.0030 | -0.0080 | -72.7% | $0.0030 | $0.0030 | $0.0030 | 2,500 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 4,200 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 1,700 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 5,100 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 2,500 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 1,500 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 300 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | +0.0010 | +10.0% | $0.0110 | $0.0110 | $0.0110 | 1,600 | |
| $0.0100 | +0.0070 | +233.3% | $0.0100 | $0.0100 | $0.0100 | 500 | |
| $0.0030 | -0.0080 | -72.7% | $0.0030 | $0.0030 | $0.0030 | 14,500 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 400 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 8,000 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 5,200 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 0 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 200 | |
| $0.0110 | -0.0010 | -8.3% | $0.0110 | $0.0110 | $0.0110 | 7,000 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0120 | 0 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0120 | 10,000 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0120 | 200 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0120 | 0 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0120 | 0 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0120 | 2,200 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0120 | 0 | |
| $0.0120 | +0.0100 | +500.0% | $0.0110 | $0.0120 | $0.0100 | 48,200 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 100 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 10,000 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 300 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 400 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 1,900 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 2,500 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 3,800 | |
| $0.0020 | -0.0001 | -4.8% | $0.0020 | $0.0020 | $0.0020 | 1,500 | |
| $0.0021 | -0.0030 | -58.8% | $0.0021 | $0.0021 | $0.0021 | 2,001 | |
| $0.0051 | +0.0001 | +2.0% | $0.0051 | $0.0051 | $0.0051 | 200 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0050 | 0 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0050 | 0 |
- Ticker
- OTC:NKGN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
NKGen Biotech Reports Long-Term Clinical Observations with Investigational Alzheimer’s Treatment Troculeucel at CTAD 2026
Latest deck · March 2026
AD/PD 2026
Conference · 21 slides
Latest news
NKGen Biotech Reports Long-Term Clinical Observations with Investigational Alzheimer’s Treatment Troculeucel at CTAD 2026
Nov 16, 2026
Closed $0.0030 (-72.7%) on Nov 16, 2026
NKGen Biotech to Present Long-Term Follow-Up of Troculeucel in Moderate Alzheimer’s Disease at CTAD 2026
Nov 9, 2026
Closed $0.011 (0.0%) on Nov 9, 2026
NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
Sep 15, 2026
Closed $0.0020 (0.0%) on Sep 15, 2026
NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
Sep 10, 2026
Closed $0.0020 (0.0%) on Sep 10, 2026
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
Apr 9, 2026
Closed $0.06 (0.0%) on Apr 9, 2026
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™
Mar 23, 2026
Closed $0.16 (+6.7%) on Mar 23, 2026
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board
Jan 22, 2026
Closed $0.06 (0.0%) on Jan 22, 2026
NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.
Dec 3, 2025
Closed $0.037 (+2.8%) on Dec 3, 2025
NKGen Biotech Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 31 in all · newest Nov 16, 2026 · oldest 2025
- Decks
- 15 decks · latest March 2026
Valuation
Statements: Year to Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- $38.58M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.88
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NKGen Biotech Inc. · OTC:NKGN | US$391,807 | US$38.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.88 |
| Protagenic Therapeutics, Inc. · OTC:PTIX | US$687,879 | US$610,970 | 0.1× | n/a | n/a | 0.6× | n/a | 0.0× | 1.21 |
| Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABT | US$580,337 | −US$2.74M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.46 |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Altamira Therapeutics Ltd. · OTC:CYTOF | US$404,655 | US$400,900 | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.64 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,500 | −US$4,070 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Median of the others | US$362,078 | −US$205,542 | 0.7× | −0.1× | 0.2× | −222.3% | 0.0× | 1.21 |
Team and board
| Officer | Role |
|---|---|
| Denise Chua | SVP, Corporate Affairs |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Jan 20, 2026 | 0.0% |
| Q3 2025 | Oct 8, 2025 | +100.0% |
| Quarter to Dec 31, 2024 | Mar 4, 2025 | |
| Q2 2024 | Sep 12, 2024 · After close | |
| Q1 2024 | May 20, 2024 · After close | |
| Q4 2022 | Mar 31, 2023 | |
| Q3 2022 | Nov 14, 2022 | |
| Q2 2022 | Aug 15, 2022 | |
| Q1 2022 | May 16, 2022 | |
| Q4 2021 | Mar 31, 2022 |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2021 | Nov 15, 2021 | |
| Q2 2021 | Aug 16, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AD/PD 2026 | Conference | 21 slides | March 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | January 2026 |
| WCN 2025 | Conference | 32 slides | October 2025 |
| ASGCT 28th Annual Meeting 2025 | Conference | 41 slides | May 14, 2025 |
| AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases | Conference | 20 slides | April 2025 |
| H.C. Wainwright 26th Annual Global Investment Conference 2024 | Conference | 60 slides | Sep 9, 2024 |
| Investor Presentation (September 2024) | Investor deck | 39 slides | September 2024 |
| Allogeneic Cell Therapies Summit 2024 | Conference | 39 slides | June 2024 |
| AD/PD Drug Development Summit 2024 | Conference | 39 slides | Apr 25, 2024 |
| Technical Presentation (March 2024) | Technical | 13 slides | Mar 25, 2024 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2024) | Investor deck | 36 slides | February 2024 |
| Graf Acquisition Corp. IV — SPAC Merger (July 2023) | SPAC merger | 66 slides | Jul 26, 2023 |
| Graf Acquisition Corp. IV — SPAC Merger (July 2023) | SPAC merger | 25 slides | Jul 17, 2023 |
| SPAC Merger (July 2023) | SPAC merger | 59 slides | July 2023 |
| Graf Acquisition Corp. IV — SPAC Merger (June 2023) | SPAC merger | 50 slides | Jun 1, 2023 |
Financings
| Raise | Date |
|---|---|
| Funding (terms to be finalized) Closed: US$17M raised Buyers: AlpineBrook Capital GP 1 Limited (provided the majority of the $17 million funding); Dr. Paul Y. Song (provided the remainder of the funding) Insiders: NKGen CEO Dr. Paul Y. Song provided part of the funding alongside AlpineBrook Use of proceeds: Purchase of NKMax Co., Ltd. shares | Sep 9, 2025 |
| Private placement of shares of common stock and warrants Closed: US$2M raised · US$0.25 a share Buyers: Japanese strategic investor ($2 million) Use of proceeds: Resources to regain compliance with reporting obligations and listing standards | Jul 16, 2025 |
| Private placement of shares of common stock and warrants Closed: US$2.65M raised Buyers: Paul Y. Song, M.D. ($2.65 million in shares of common stock and warrants) Insiders: Chairman & CEO Paul Y. Song, M.D. invested $2.65 million cash in shares of common stock and warrants Use of proceeds: Accelerate Phase 2 Alzheimer's trial, reduce payables, general working capital and public company compliance expenses | May 8, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | 0 | 77.0K | 426.0K | |
| Cost of revenue | 1.20M | 18.0K | 30.0K | |
| Gross profit | -1.20M | 59.0K | 396.0K | |
| Research and development | 10.7M | 15.7M | 16.7M | 14.7M |
| Selling, general and administrative | 16.3M | 14.1M | 7.66M | 7.58M |
| Operating income | -27.0M | -29.7M | -24.3M | -21.9M |
| Depreciation and amortization | 1.31M | 1.20M | 1.21M | 1.24M |
| EBITDA | -25.7M | -28.5M | -23.1M | -20.6M |
| Interest expense | 2.72M | 745.0K | 2.31M | 1.31M |
| Income before tax | -44.2M | -82.9M | -26.7M | -23.3M |
| Income tax | 53.0K | 7.00K | 7.00K | 5.00K |
| Net income | -44.3M | -83.0M | -26.8M | -23.3M |
| Earnings per share, basic | -1.54 | -5.38 | -1.25 | -1.08 |
Balance sheet
| Line | FY2025 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Cash and equivalents | 26.0K | 117.0K | 351.0K | |
| Receivables | 24.0K | 26.0K | 96.0K | 67.0K |
| Inventory | -250.0K | 133.0K | 172.0K | |
| Current assets | 24.0K | 1.93M | 350.0K | 612.0K |
| Property, plant and equipment | 15.9M | 17.4M | ||
| Total assets | 24.0K | 16.5M | 16.3M | 18.1M |
| Accounts payable | 11.0M | 975.0K | 1.71M | |
| Current liabilities | 39.5M | 14.7M | 55.7M | |
| Long-term debt | 9.93M | |||
| Total debt | 19.9M | 12.0M | 52.0M | |
| Total liabilities | 75.2M | 14.8M | 56.1M | |
| Shareholders' equity | -58.7M | 1.56M | -38.1M | |
| Shares outstanding | 28.8M | 15.4M | 21.5M | 21.5M |
Cash flow
| Line | FY2025 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Cash from operations | -20.9M | -21.9M | -22.6M | -19.5M |
| Capital spending | 0 | -48.0K | -163.0K | -459.0K |
| Free cash flow | -20.9M | -22.0M | -22.7M | -20.0M |
| Cash from investing | -13.0K | -48.0K | -163.0K | -459.0K |
| Cash from financing | 20.9M | 22.2M | 22.5M | 20.2M |
| Change in cash | 1.70M | 159.0K | -234.0K | 152.0K |
Cap table
Built by 6ix from NKGen Biotech Inc.’s releases · as of Sep 9, 2025
- Common shares
- 130,602,230
- Fully diluted
- 130,602,230
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 130,602,230 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 130,602,230 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kathleen Scott Other companies: ARS Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Nov 8, 2022); Dermata Therapeutics, Inc. (Director · Since at least Aug 12, 2021); Histogen Inc (Director · Nov 18, 2019 – Nov 18, 2019 · Past) | Director · Sep 29, 2023 – Dec 6, 2024 · Past |
| Alana B McNulty Other companies: Janux Therapeutics, Inc. (Director · Since at least Sep 7, 2021); eFFECTOR Therapeutics Inc (Chief Business Officer · Aug 25, 2021 – Jun 20, 2022 · Past) | Director · Sep 29, 2023 – Sep 29, 2023 · Past |
| Denise Chua | SVP, Corporate Affairs · Since at least Sep 15, 2026 |
| Marco Gottardis | Director · May 23, 2024 – Jul 11, 2024 · Past |
| Paul Y Song | Chief Executive Officer · Sep 28, 2023 – May 5, 2025 · Past |
| Pierre Gagnon | Chief Operating Officer · Sep 29, 2023 – Feb 12, 2024 · Past |
| Sangwoo Park | Director · Sep 29, 2023 – Dec 13, 2023 · Past |
| Yong Man Kim | CSO and CIO · Sep 29, 2023 – Feb 12, 2024 · Past |
Log in to ask 6ix AI your own questions about NKGen Biotech Inc.